Physician profile
Patrick Edward Tolan
NPI 1962985416
$14,988.22
in general payments reported to CMS, 2019-2025
30 companies · $4,257 in 2025
The $4,257 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,722 · 2022: $2,960 · 2023: $2,312 · 2024: $3,737 · 2025: $4,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,859 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,859.32 |
| Education | $446.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,627.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,490.64 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,161.12 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $1,134.04 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,096.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $999.66 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $852.92 | 2021-2025 | |
| Amgen INC. | $839.57 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $717.98 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $586.10 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $540.09 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $524.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $512.58 | 2021-2025 | |
| Leo Pharma INC. | $509.44 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $420.07 | 2021-2025 | Aklief, Nemluvio, Epsolay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $341.97 | 2021-2022 | |
| Dermavant Sciences, INC. | $306.66 | 2023-2024 | Vtama |
| Ucb, INC. | $287.51 | 2021-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $285.65 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $152.73 | 2024 | Daxxify |
| Lnhc, INC | $140.88 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $113.18 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Organon LLC | $103.84 | 2025 | Vtama, Hadlima |
| Genentech USA, INC. | $61.75 | 2021 | |
| Almirall LLC | $60.22 | 2021-2025 | Seysara |
| Allergan, INC. | $38.65 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $30.32 | 2024 | Ycanth |
| Biofrontera INC. | $21.39 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Nabriva Therapeutics, Plc | $16.63 | 2022 | |
| Organogenesis INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.